Teva Pharmaceuticals

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

No narrative on renewables strategy in the firm's most recent reports.

No narrative on durable removals approach in the firm's most recent reports.

• EHS management system and climate change mitigation

  Teva continued implementation of its global EHS management system in 2024 across all countries of operation, with proactive compliance evaluation, EHS leading indicators, and continued promotion of a climate change mitigation and adaptation strategy according to international standards. Water management is being addressed with a scarcity-focused approach to conservation.

• Manufacturing footprint consolidation

  Teva operates 34 finished dosage and packaging plants in 27 countries and 13 API production facilities, and has closed or divested a significant number of manufacturing plants in recent years as part of network optimization under the Pivot to Growth strategy. The classification of the API business and Japan business as held for sale further reduces operated emissions scope.

• Pharmaceutical pollutants — Urban Wastewater Treatment Directive

  In November 2024, the EU adopted revisions to the Urban Wastewater Treatment Directive requiring pharmaceutical companies to pay for a majority of the costs to remove micropollutants from wastewater. This represents a new product stewardship cost lever extending Teva's environmental responsibility downstream into water treatment infrastructure.

• Supplier audit and supply chain management

  Teva implemented a supplier audit program to ensure suppliers meet quality and operational standards. The Company sources APIs from its own facilities plus suppliers in Europe, Asia and the Americas, and continues to strengthen its third-party operations unit to meet cost, supply security and quality targets sustainably.